Scientists, clinicians, and industry leaders from around the world attend the Obesity 2009 conference to hear the most renowned leaders in the obesity field present cutting-edge research. More than 2,500 attendees are expected to be there. Click here for the Exhibitor Prospectus.
Exhibitors receive:
- Complimentary Exhibit Hall guest passes for customers and prospects
- Complimentary tickets to the Opening Reception on October 24, 2009
- A 50-word description of their company listed in the Final Program, distributed to every attendee
The benefits don't end there, sign up now! |
Spotlight your company’s message and
reach prospective clients by participating
in one or more Obesity 2009 sponsorship
opportunities!
Learn more about Corporate Sponsorship Opportunities at Obesity 2009.
If you are interested in Corporate-Sponsored Symposia, please read the application and guidelines and contact us today!
Sponsorship increases awareness of your company’s
commitment to obesity research, prevention,
treatment, and management.
The Obesity Society is pleased to offer a new service to our Corporate Symposium Sponsors. We now have the ability to record your symposium, convert it to an enduring material format, and host it on the Internet for all to view. Learn more!
For all booth locations, check out the Obesity 2009 floorplan. |
|
| BOOTH NUMBER |
COMPANY |
217 |
ACCUSPLIT, Inc. |
508 |
ActiGraph |
125 |
Adipo Gen |
218 |
AEI Technologies |
505 |
Ajinomoto U.S.A., Inc. |
103 |
Allergan |
525 |
ALPCO Diagnostics |
208 |
American Institute for Cancer Research |
215 |
American Society of Nutrition |
101 |
Bariatrix Nutrition Corporation |
102 |
BioPorto Diagnostics |
111 |
Bruker Optics |
512 |
Canadian Obesity Network |
502 |
Columbus Instruments |
523 |
Dyets Inc. |
519 |
Echo Medical Systems |
205 |
Fitsmi.com, Created by Life180, Inc. |
201 |
GE Healthcare Lunar |
117 |
Health Management Resources (HMR) |
123 |
Healthy Buddies |
106 |
HFCSfacts.com |
116 |
Hologic |
202 |
IASO |
513 |
iWorks Systems, Inc. |
506 |
Jenny Craig |
105 |
Life Measurement, Inc. |
211 |
Mercodia |
119 |
Meso Scale |
127 |
Millipore |
308 |
Nature Publishing Group |
122 |
Nestlé Healthcare Nutrition, Inc. - Optifast® |
509 |
New England Peptide, LLC |
516 |
Noldus Information Technology |
225 |
Overeaters Anonymous |
115 |
Philips Respironics |
227 |
Phoenix Pharmaceuticals, Inc. |
100 |
Profil Institute for Clinical Research |
300 |
Purina TestDiet |
510 |
QuesGen Systems, Inc. |
124 |
RayBiotech |
511 |
Research Diets |
121 |
RTI International |
524 |
Sable Systems International Inc. |
301 |
Seahorse Bioscience Inc. |
307 |
Sometech Corporation |
521 |
Structure House |
131 |
Taconic |
501 |
Tanita Corporation |
206 |
T-Fal |
109 |
TOPS Club |
515 |
TSE Systems, Inc. |
224 |
VacuMed |
216 |
Weight Management Dietary Practice Group of ADA |
107 |
Wiley Blackwell |
200 |
XXL Rehab |
520 |
ZenBio |
Obesity 2009 Corporate Sponsors
GOLD SPONSOR &
CONFERENCE LANYARD SPONSOR
SILVER SPONSOR
INDEPENDENT EDUCATIONAL GRANT
Obesity 2009 Corporate-Sponsored Symposia
The Obesity Epidemic! Exploring Emerging Strategies for Weight Control and Risk Reduction
Supported by Orexigen
Sunday October 25, 2009 7:15-9:00PM
Treatment of obesity poses complex management problems for clinicians. In this program, clinicians will review the data on risk assessment and evidence of the health benefits of weight loss that helps drive therapeutic decisions. The array of treatment options – from lifestyle choices to medications to surgical intervention – will be reviewed, with practical solutions for addressing barriers to treatment, as well as other practice issues. With a limited number of approved weight loss medications currently available, clinicians will also look ahead to emerging therapeutic options designed to control food intake and encourage weight loss.
Register Now!
Stop Cardiometabolic Risk Before It Stops You: Exploring New Advances in the Medical Management of Obesity and Type 2 Diabetes
Supported by Amylin-Lilly
Monday October 26, 2009
Diabetes, hypertension, dyslipidemia and obesity are closely related metabolic processes that significantly increase a patient’s risk of cardiovascular disease. In this program, clinicians will discuss how insulin resistance contributes to these cardiometabolic diseases and how understanding these relationships can influence disease management. The dynamics of the incretin system and mechanism of incretin-based therapies will be discussed, to offer a state-of-the-science update on an important pathway in treating diabetes. Clinicians must synthesize understanding of pathophysiology with therapeutic action, and the panel will discuss management strategies for controlling weight, controlling lipid and glycemic levels to achieve the best outcomes for patients.
Register Now!
For more information on Exhibits, Sponsorships and Corporate-Sponsored Symposia,
Contact our Meeting Coordinator, Tricia Cavallo |
